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Abstract
Accumulation of misfolded and aggregated forms of tau protein in the brain is a neuropathological hallmark of tauopathies, 
such as Alzheimer’s disease and frontotemporal lobar degeneration. Tau aggregates have the ability to transfer from one cell 
to another and to induce templated misfolding and aggregation of healthy tau molecules in previously healthy cells, thereby 
propagating tau pathology across different brain areas in a prion-like manner. The molecular mechanisms involved in cell-to-
cell transfer of tau aggregates are diverse, not mutually exclusive and only partially understood. Intracellular accumulation 
of misfolded tau induces several mechanisms that aim to reduce the cellular burden of aggregated proteins and also promote 
secretion of tau aggregates. However, tau may also be released from cells physiologically unrelated to protein aggregation. 
Tau secretion involves multiple vesicular and non-vesicle-mediated pathways, including secretion directly through the 
plasma membrane. Consequently, extracellular tau can be found in various forms, both as a free protein and in vesicles, such 
as exosomes and ectosomes. Once in the extracellular space, tau aggregates can be internalized by neighboring cells, both 
neurons and glial cells, via endocytic, pinocytic and phagocytic mechanisms. Importantly, accumulating evidence suggests 
that prion-like propagation of misfolding protein pathology could provide a general mechanism for disease progression 
in tauopathies and other related neurodegenerative diseases. Here, we review the recent literature on cellular mechanisms 
involved in cell-to-cell transfer of tau, with a particular focus in tau secretion.
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Abbreviations
AD  Alzheimer’s disease
AGD  Argyrophylic grain disease
CBD  Corticobasal degeneration
CSF  Cerebrospinal fluid
EM  Electron microscopy
ER  Endoplasmic reticulum
FGF2  Fibroblast growth factor 2
FTD  Frontotemporal dementia
FTDP-17  Frontotemporal dementia with Parkinsonism 
in chromosome 17
GAG  Glycosaminoglycan
HSPG  Heparin sulfate proteoglycans
IDP  Intrinsically disordered protein
MAPS  Misfolding-associated protein secretion
MT  Microtubules
MTBD  Microtubule-binding repeat domain
MVB  Multivesicular body
NFT  Neurofibrillary tangles
PD  Parkinson’s disease
PiD  Pick’s disease
PI(4,5)P2  Phosphatidyl inositol 4,5 phosphate
PFF  Pre-formed fibrils
PM  Plasma membrane
PrP  Prion protein
PS  Phosphatidyl serine
PSP  Progressive supranuclear palsy
TBI  Traumatic brain injury
UPS  Unconventional protein secretion
Introduction
Demographic aging is increasing the prevalence and soci-
etal cost of dementia. The number of people living with 
dementia is expected to reach 130 million people by 2050 
(World Alzheimer Report 2015). Most chronic neurodegen-
erative diseases are characterized by progressive accumula-
tion of protein aggregates in the nervous system. A common 
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neuropathological hallmark in Alzheimer’s disease (AD), 
the most common type of aging-related dementia, is cerebral 
accumulation of neurofibrillary tangles (NFT), composed 
of aggregated tau protein, which appear to spread from one 
affected brain region to other areas of the brain as the disease 
progresses. Similar accumulation of tau inclusions in brain 
is observed in, e.g., frontotemporal dementia (FTD), pro-
gressive supranuclear palsy (PSP), corticobasal degeneration 
(CBD) and Pick’s disease (PiD). Slow spreading of patho-
logically misfolded tau protein may also be a central event in 
development and progression of chronic traumatic encepha-
lopathy (CTE), which is often associated with repeated head 
injuries. The cellular mechanisms of spreading of patho-
logical proteins, such as tau, α-synuclein, β-amyloid peptide 
(Aβ) and TDP-43, have been receiving increasing attention, 
and better understanding of the spreading mechanisms is 
expected to accelerate development of disease-modifying 
therapies for these devastating neurodegenerative diseases.
Tau is a microtubule‑binding protein enriched 
in neurons
Tau is one of the many microtubule-associated proteins 
(MAP) that have an important function of regulating micro-
tubules (MT) to ensure proper cytoskeletal organization 
and trafficking [1], which is particularly important in highly 
polarized neuronal cells whose functionality and viability 
depend on transport of cellular cargo to and from axonal and 
dendritic peripheries [2–4]. Tau has important physiological 
functions in regulating MT, including MT polymerization, 
stabilization and suppression of MT dynamics. Dysregula-
tion of the tau–MT complex leads to tau detachment and 
instability and disassembly of MTs, eventually leading to 
perturbation of MT-dependent transport and impaired main-
tenance of cellular polarity and viability [4, 5].
Tau is present in neurons and, to a lesser degree, in glial 
cells [6, 7]. Tau is mainly an axonal protein in mature neu-
rons, but it can also be found in the nucleus, mitochondria, 
dendrites, synapses, and at the plasma membrane (PM) 
[8–13]. This localization pattern suggests that besides the 
main function of MT regulation, tau may have other roles 
in cells.
Synaptic tau has been reported to be involved in synaptic 
development of newborn hippocampal neurons [14]. Also, 
a role for tau in neuronal activity has been proposed, as tau 
knockout mice display impaired long-term depression in the 
hippocampus [11]. Tau also interacts with nucleic acids and 
can localize to the nucleus, and upon binding to DNA it 
promotes DNA stability [15], suggesting that tau may have a 
role in DNA protection [16]. Finally, several domains of the 
tau protein have the ability to interact with lipids and mem-
branes [17], and one of tau kinases, Fyn, is mainly located 
in PM microdomains called lipid rafts, where tau can also be 
recruited [18]. It is also possible that tau localized at the PM 
occupies a role as a signaling regulator, via its interaction 
with membrane receptors [19, 20].
Tau is encoded by the MAPT gene, which in humans is 
located on the chromosome 17. Tau is composed of 16 exons 
which give rise to six different splicing isoforms, which 
span from 352 to 441 amino acids (aa) [21], depending on 
alternative splicing of exons 2, 3 and 10 (Fig. 1a). Exons 2 
and 3 encode for 29 amino acid repeats, both located at the 
N-terminal part of the protein, and alternative splicing of 
exons 2 and 3 or exon 2 alone produces three N-terminal 
protein variants 0N, 1N (additional 29 aa) or the less abun-
dant 2N (additional 58 aa). Exon 10 encodes for one of the 
four possible microtubule-binding repeat domains (MTBD), 
which are 31–32 aa long imperfect repeat sequences, located 
in the C-terminal half of the tau protein and affecting both 
microtubule-binding affinity and fibrillization properties of 
tau. Splicing isoforms of tau contain either three (3R) or 
four (4R) MTBDs, which affects their microtubule-binding 
affinity (4R > 3R) and also their propensity for aggregation. 
The ratio between 3R and 4R isoforms is developmentally 
regulated as human fetal tau consists mostly the shortest 
form 0N3R, while in the adult brain all six isoforms coexist. 
Also, species-specific differences exist, as for example adult 
mice display exclusively 4R-tau isoforms [22].
Different functional domains characterize the tau protein 
(Fig. 1a). The N-terminal projection domain consists of resi-
dues 1–150 (of the longest isoform) and it regulates micro-
tubule binding even though it is not directly involved in the 
physical interaction [23]. Absence of the N-terminus alters 
cellular localization of tau, promoting cytosol to nucleus 
relocalization [24]. It has also been suggested that the 
N-terminal projection domain mediates PM localization of 
tau via annexin-2 interaction [25]. The proline-rich domain 
occupies the central portion of tau from residue 151–243. It 
represents the most disordered part of the protein and serves 
as an interaction site for Src homology-3 (SH3) proteins, 
in particular the Fyn kinase [26], as well as an interaction 
site for DNA and RNA [27, 28]. The MTBDs, as the name 
suggests, interact with microtubules but also with actin, 
orchestrating the order and stability of the cytoskeleton. 
Several proteins associated with neurodegenerative disor-
ders, including α-synuclein, presenilin-1, FUS, and TIA-
1, interact with the MTBDs and the proline-rich domains 
of tau, suggesting that the structural composition and pro-
tein–protein interactions of tau could play an important role 
in pathological processes [29].
Mutations in the MAPT gene have been linked to heredi-
tary dominant frontotemporal dementia with parkinsonism 
in chromosome 17 (FTDP-17), which includes diverse clini-
cal syndromes as well as diverse anatomical distribution of 
tau inclusions depending on the specific mutations [30]. First 
mutations in the MAPT gene were found in 1998 [31, 32] 
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linked to dominant hereditary FTDP-17, and today there are 
over 50 known pathogenic mutations in the MAPT gene, 
mostly located in exons 9–12 [30]. Such mutations can affect 
tau both at the protein level, for example by altering micro-
tubule-binding properties (e.g., K257T, G272V, P301L, 
V337M and R406W mutations), and at the RNA level, 
shifting the splicing toward overproduction of 4R-tau (e.g., 
N279K, N296H, P301S, S305I mutations) [33, 34]. This is 
relevant because isoforms containing exon 2 and exon 10 are 
more aggregation prone compared to isoforms containing 
only exon 3, due to the presence of the VQIINK hexapeptide 
(encoded by exon 10) that mediates homo-oligomerization 
[35, 36]. Additionally, alterations in the ratio of physiologi-
cally produced 3R-tau and 4R-tau may cause tau dysfunction 
in cells, even in the absence of mutations affecting splic-
ing of exon 10. For instance, 4R-tau binds to microtubules 
with higher affinity compared to the 3R isoforms, promoting 
microtubule assembly and oversaturation of the available 
binding sites [37]. In turn, an imbalance between 4R-tau and 
3R-tau isoforms may cause accumulation of unbound 4R-tau 
in the cytosol, which would favor tau aggregation.
Structural plasticity and aggregation of tau
Although tau is considered a natively unfolded protein 
[sometimes also called an intrinsically disordered protein 
(IDP)], its ability to adopt various structural states is impor-
tant to its functions and pathological properties. Since the 
first report on tau structure in 1977 [38], there have been 
numerous approaches and reports addressing tau structure 
in various contexts (reviewed in [39]). While the intrinsi-
cally disordered nature of tau precludes the use of crystallo-
graphic methods, circular dichroism, nuclear magnetic reso-
nance (NMR) spectroscopy, and more recently cryogenic 
Fig. 1  The structural basis of 
tau function and aggregation. a 
The domain structure of human 
tau protein. Location of the 
projection domain, proline-rich 
domain, MTBDs, and the parts 
of tau protein encoded by the 
alternatively spliced exons 2, 
3 and 10 are shown on top of 
the longest tau isoform (2N4R, 
441 aa). Below the location of 
key phosphorylated residues, 
the two hexapeptides, the two 
cysteines and examples of 
FTLD-associated mutations 
in the MTBDs are shown. b 
Microtubules (blue and green) 
are formed by the assembly of 
α- and β-tubulin dimers into 
protofilaments that associate 
laterally into hollow tubes. Tau 
(red) binds to the surface of 
microtubules interacting with α- 
and β-tubulin via the MTBDs. 
The image was prepared 
based on a cryo-EM structure 
of microtubule-associated 
synthetic tau (PDB: 6CVN). c 
Structure of a paired helical fila-
ment (PHF) fragment isolated 
from AD brain. The filaments 
are formed of anti-parallel 
β-sheets, with the protofila-
ment core formed by the four 
MTBDs of tau. The location of 
the tau hexapeptide sequence is 
indicated. Image was prepared 
based on a cryo-EM structure 
(PDB: 5O3L)
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electron microscopy (cryo-EM) have provided insight 
into conformational states of tau, in soluble physiological 
state, bound to microtubules or in the form of pathological 
aggregated states. It was also recently suggested that under 
physiological conditions tau monomers may adopt stable 
yet diverse conformations, opening a new perspective for 
understanding the plasticity of tau structure in physiology 
and in pathology [40, 41].
Multiple tau monomers bind in tandem to the surface of 
microtubule (MT) protofilaments. The conserved MTBDs 
adopt similar extended structures along the microtubules, 
stabilizing the interface between tubulin dimers [42] 
(Fig. 1b), while the N-terminal projection domain extends 
away from the MT protofilament surface. While microtubule 
binding does not promote adoption of distinct secondary 
structures, the MTBDs may have some α-helical propensity. 
Also, interaction with membranes may facilitate adoption of 
temporary secondary structures.
The ability of tau to aggregate is encoded in its own 
sequence. Especially, two hexapeptides present in the 
MTBDs (VQIVYK and VQIINK) are fundamental for 
aggregation and formation of the tau filaments [36, 43]. One 
of the hexapeptides (VQIVYK) is present in all tau isoforms 
in the third MTBD, while the other one (VQIINK), since 
it is located in the second MTBD encoded by exon 10, is 
only present in the 4R isoforms. This partially explains the 
higher propensity of 4R isoforms to aggregate compared to 
3R isoforms. Local structural changes of the MTBDs via 
exposure of the VQIVYK/VQIINK motifs may determine 
the conversion of an inert tau monomer into a pathologi-
cally aggregated form [40]. Tau dimerization, the first step 
in tau oligomerization, can occur through any combination 
of these two motifs, which form the nucleation center where 
further tau dimers and tau monomers can be recruited to 
eventually constitute oligomers. Of particular importance 
are also two cysteine residues located in R2 and R3, which 
form disulfide bridges during tau dimerization and which 
have been found to constitute a critical step in the formation 
of tau fibrils [44]. Elongated oligomers then acquire a more 
ordered β-sheet structure, and finally form paired helical 
filaments (PHFs), which represent the building blocks of 
the neurofibrillary tangles (NFT) [45]. Cryo-EM structures 
of tau filaments extracted from AD brain confirmed the 
β-sheet-dominant pathological conformation [46], confirm-
ing previous findings [47]. Straight and paired helical fila-
ments appear to be ultrasctructural polymorphs, both sharing 
the same basic structural architecture (Fig. 1c).
The widely studied P301L mutation, found in some 
patients with FTDP-17, occurs near one of the hexapeptides 
and promotes tau aggregation [31]. On the other hand, arti-
ficial mutations in the hexapeptides, such as proline inser-
tion that distort the β-sheet structure, reduce tau aggrega-
tion [48]. In addition, the cellular environment, such as the 
presence of anionic membranes, also promotes tau aggrega-
tion [49, 50]. A similar effect results also from polyanions 
such as heparin and RNA [51, 52].
Among the many post-translational modifications that 
modulate tau functions, phosphorylation is of particular 
interest because of its role in the pathological processes, as 
the deposits of insoluble tau found in the brains of tauopa-
thy patients contain hyperphosphorylated tau [53–56]. 
Since the first report that classified tau as a phospho-protein 
[38], there are now at least 85 known phosphorylation sites 
(mostly serines and threonines, but also tyrosines). Tau is 
physiologically constantly phosphorylated and dephospho-
rylated to ensure regulation of proper functions, but when 
the balance is shifted toward phosphorylation, tau affinity 
for microtubules decreases [57]. This results in an increase 
in cytosolic tau, which becomes more vulnerable to aggre-
gation [58]. Additionally, abnormally phosphorylated tau 
is able to sequester other microtubule-associated proteins 
(MAP), further worsening microtubule destabilization [57]. 
It is now well established that there is a strong connection 
between aberrant phosphorylation and self-aggregation of 
tau into oligomers and higher-order aggregates [36], despite 
the fact that a complete pathological phosphorylation pattern 
has not been identified yet. The neurodegeneration-associ-
ated consequences of tau hyperphosphorylation also include 
impaired axonal transport [59], cellular relocalization of tau 
to the somatodendritic compartment and synaptic loss [60]. 
Synaptic dysfunction can occur both pre-synaptically, where 
phosphorylated tau has been shown to interfere with synap-
tic vesicles [61], and post-synaptically via downregulation 
of AMPA receptors [62]. Interestingly, it was shown that 
synaptic terminals of AD brains and transgenic P301L mice 
do not contain more tau compared to control brains, indicat-
ing that there is no relocalization to synapses in pathological 
conditions. Instead, synaptic tau was hyperphosphorylated, 
suggesting a role for phosphorylation in the spreading of the 
disease as well [63, 64]. Additionally, hyperphosphoryla-
tion is linked to impaired degradation of tau by the ubiqui-
tin–proteasome system [65] and to tau secretion. It was in 
fact shown that abnormally phosphorylated tau is secreted 
more efficiently than non-phosphorylated tau, at least in cell 
lines [66, 67]. Finally, abnormal tau phosphorylation impairs 
its ability to interact with tau partners, therefore altering 
normal physiological properties of tau [68].
Tau phosphorylation state is a result of a tightly regu-
lated balance of actions between many cellular proteins: 
mainly kinases that phosphorylate tau and phosphatases that 
dephosphorylate it. Tau kinases are divided into three dif-
ferent groups: (1) serine/threonine proline-directed kinases, 
which include GSK3, CdK5, MAPKs and other stress-
activated kinases; (2) serine/threonine non-proline-directed 
kinases, which include DYRK1A, PKA, CaMKII and CK1; 
and (3) tyrosine kinases, such as Fyn and Src [69]. Some 
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kinases, such as GSK3β, MAPK, CK1δ and Cdk5, are found 
in neurofibrillary tangles, suggesting a direct link between 
phosphorylation and disease progression [55]. The activity 
of phosphatases like PP2A, one of the principal neuronal 
protein phosphatases, is dramatically decreased in the brain 
of AD patients [70]. This suggests that not only upregu-
lated kinase activity, but also downregulated phosphatase 
activity is involved in pathological phosphorylation of tau. 
There likely exist complex regulatory loops that maintain 
tau phosphorylation in homeostasis. For instance, impair-
ment of the Akt/mTOR pathway may alter the physiologic 
phosphorylation balance between GSK3β and PP2A, as Akt 
inhibits GSK3β, which in turn inhibits PP2A [22].
Our understanding of the intricate mechanism of tau 
phosphorylation equilibrium is further complicated by an 
increasing amount of evidence that challenge the classical 
view that correlates hyperphosphorylation with neurodegen-
eration [71]. For instance, phosphorylation sites that pro-
mote tau disassembly from the microtubules not only favor 
tau aggregation, but can actually inhibit it [72]. In line with 
these results, Arendt and colleagues suggested that hyper-
phosphorylation of tau may have a physiological role, pos-
sibly related to synaptic plasticity [73].
These observations lead to a very important conclusion, 
which was suspected for a long time but only recently exper-
imentally proven: considering all the factors that affect tau 
aggregation (mutations, isoform composition, post-transla-
tional modifications and localization), it seems unlikely that 
a single form of tau is responsible for its pathological effects. 
It is more likely that a plethora of different pathological tau 
species with different properties accounts for the heterogene-
ity observed in tau-mediated pathology [74]. Moreover, tau 
pathology is rarely exclusively present in any of the tauopa-
thies, as other pathological proteins and other phenotypes 
often accompany tau pathology and dysfunction. There may 
therefore be some common pathways that bring together dif-
ferent proteins with very different cellular functions, pos-
sibly causally linking development of distinct pathologi-
cal features and resulting in synergistic modes of toxicity. 
For example, in mouse model of AD, soluble Aβ promotes 
development of tau pathology [75, 76]. In tau, presenilin1 
and APP transgenic mice, amyloid pathology precedes 
development of NFT pathology [77]. Tau and α-synuclein 
promote fibrillization of each other [78] and insoluble forms 
of tau and α-synuclein have been found co-aggregating in 
Lewy bodies, the characteristic pathological deposits of Par-
kinson’s disease (PD) [79]. Moreover, genetic studies have 
linked variants of the tau gene, MAPT, to susceptibility of 
developing sporadic PD [80, 81], and mutations in MAPT 
are associated with dementia with parkinsonism [31]. It is 
therefore clear that the neuropathological features that char-
acterize different tauopathies could originate from differ-
ent types of tau modifications and interactions with other 
cellular proteins, defining different strains of pathological 
tau with different molecular properties.
Tau inclusions in neurodegenerative diseases
Tau dysfunction can lead to a wide variety of human disor-
ders, called tauopathies, which include very different clinical 
syndromes and a constellation of pathological hallmarks. 
The principal tauopathies include AD, FTDP-17, the spec-
trum corticobasal degeneration/progressive supranuclear 
palsy (CBD/PSP), Pick’s disease and argyrophilic grain 
disease (AGD). A list of the main tauopathies, with their 
key features, is presented in Table 1.
Tauopathies are typically associated with dementia and 
motor impairments, but the clinical picture can vary between 
different disorders and even within syndromes, ranging from 
minor cognitive impairments [82] to the severe behavioral 
changes and cognitive and motor impairments of FTDP-17 
[83]. Similarly, while it is quite common for the majority of 
tauopathies to be characterized by generalized cortical atro-
phy and ventricle enlargement, which partially explains the 
overlapping symptoms, the progression pattern and affected 
brain areas may vary [84]. While biochemical, genetic, path-
ological and clinical similarities between tauopathies can 
facilitate understanding of the general principles of how tau 
pathologies develop, they also complicate the diagnosis and 
classification of different tauopathies.
Tauopathies can be classified as primary or secondary, 
depending whether tau inclusions constitute the main path-
ological hallmark or whether other pathological proteins 
significantly contribute to the pathogenesis of the disease 
[84]. For instance, AD, the most common neurodegenerative 
disease and one of the main models for the investigation of 
tau pathology, is a secondary tauopathy to amyloid plaques, 
which are largely composed of aggregated Aβ peptides [85]. 
Primary tauopathies include FTDP-17, CBD/PSP, PiD and 
AGD. Majority of tauopathies are sporadic, but for example 
FTDP-17 is strictly inherited and all the different clinical 
and neuropathological subtypes of FTDP-17 are caused by 
different mutations in the MAPT gene [86]. Notably, regard-
ing the classification of nervous system diseases, it was 
recently proposed that the term FTDP-17 should be retired 
and FTDP-17 cases should be considered as familial forms 
of frontotemporal lobar degeneration with tau-immunoreac-
tive inclusions (FTLD-tau) [87].
Classification of tauopathies can also be done based on 
the tau isoforms present in the inclusions and morphology 
of the tau filaments found in the pathological deposits. 
While AD and FTDP-17 are mixed 3R and 4R tauopathies, 
reflecting the physiological ratio of expressed tau isoforms 
in the healthy brain [88], CBD/PSP, and AGD are clas-
sified as 4R tauopathies, as the pathological inclusions 
are predominantly constituted by 4R-tau [84]. The only 
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known tauopathy characterized by inclusions of 3R-tau is 
Pick’s disease [89]. Tau inclusions also differ regarding 
the morphology of tau filaments and the cell types where 
they are deposited. The evidence that different missense 
mutations in the MAPT gene can lead to different filament 
morphology gives an idea of the possible morphological 
heterogeneity of tau aggregates. For instance, N279K 
mutation promotes formation of tau bundles of varying 
thickness [90], while P301L mutation causes accumula-
tion of twisted ribbons and stranded filaments [32] and 
S305I mutation promotes formation of straight and tubular 
filaments [91].
Specific tauopathies may display specific types of tau 
inclusions, as shown by argyrophilic grains and Pick’s bod-
ies. Pick’s bodies are round and well-demarcated structures, 
normally occurring one per cell and constituted by hetero-
geneous types of tau filaments [92]. Unlike Pick’s bodies, 
argyrophilic grains result positive for Gallyas staining and 
are characterized by a spindle shape mostly composed of 
straight tau filaments [93]. CBD/PSP and FTDP-17 on the 
other hand display pleomorphic neuronal tangle-type inclu-
sions, which vary in size, shape and distribution [94–96]. 
Moreover, in the majority of tauopathies glial inclusions, in 
the form of coiled bodies, are found in oligodendrocytes [97, 
98], astrocytic tufts and astrocytic plaques [99].
A recurring theme in neurodegenerative diseases is the 
co-occurrence of protein inclusions composed of different 
proteins in the same patient [68, 100]. For example, tau and 
α-synuclein inclusions co-occur in multiple diseases includ-
ing Lewy body variant of AD, DLB and PD with dementia 
[101, 102]. Despite the fact that tau and α-synuclein are 
distinct proteins that contribute to different disease-specific 
pathologies, multiple lines of evidence suggest that tau and 
α-synuclein interact, modulate the aggregation of each other 
and coexist in pathological inclusions in human brain [103]. 
Apart from the potential gain-of-toxic-function relationship 
that feeds forward the aggregation of each other, tau and 
α-synuclein may also overlap in their loss-of-function effects 
via a partially shared protein interactome [68]. Similar cross 
talk may occur between other disease-associated aggregating 
proteins, e.g., between tau and TDP-43 [104].
In AD, autopsy studies have demonstrated that patho-
logical Aβ and tau inclusions accumulate in stereotypical 
spatial patterns over the course of the disease with the AD-
related tauopathy occurring downstream of amyloid pathol-
ogy [105]. Development of PET tracers specifically binding 
to the aggregated forms of Aβ and tau now allows a better 
understanding of the temporal relationship of the amyloid 
and neurofibrillary pathologies in the human brain. It seems 
that the level of tau deposition in the temporal lobe is more 
closely related to dementia status and can predict cognitive 
performance better than Aβ deposition in any brain region 
[106].
Spreading of tau pathology in brain
It is well established that in AD the development of tau 
pathology occurs in a hierarchical pattern of accumula-
tion starting from the layer II of entorhinal cortex (EC) and 
spreading toward cortical regions, as originally proposed by 
the findings of Heiko and Eva Braak [107]. Increased cer-
ebrospinal fluid (CSF) levels of tau are associated with faster 
rate of cognitive decline and overall worse clinical outcome 
in AD [108, 109]. Accumulating evidence suggests that in 
most neurodegenerative diseases, inclusions of misfolded 
and pathological proteins spread along neuroanatomically 
connected areas of the brain in a way that remind the spread 
of pathological prion protein (PrP) [110]. It was previously 
thought that stage-wise progression of neurodegeneration 
would reflect a differential spatial and temporal vulnerabil-
ity of different brain areas to protein misfolding pathology 
and toxicity, therefore explaining the anatomical progression 
of the pathological inclusions [111]. However, the concept 
that pathologically misfolded protein species, such as tau 
aggregates, can be released from a cell and internalized by a 
neighboring cell from the extracellular space in a prion-like 
manner [110] has provided a new way of approaching the 
progression of tauopathies and other related neurodegenera-
tive diseases.
Tau is able to serve as a hub for its own aggregation and 
as a seed for further misfolding in a process called templated 
misfolding. Once aggregated, the pathological tau seeds can 
be transmitted from one cell to another propagating pathol-
ogy from affected to healthy cells and to previously unaf-
fected brain areas. In 2009, a pioneer study demonstrated 
that tau extracted from tau(P301S) transgenic mice, which 
carries one of the frontotemporal dementia tau mutations 
and develops tau inclusions, and injected into healthy mice 
that do not normally develop tau inclusions, lead to develop-
ment of tau pathology [112]. The authors detected extensive 
distribution of phosphorylated, filamentous and insoluble 
tau by silver staining and antibody labeling in the areas near 
the injection, as well as in neighboring areas of the brain, 
indicating that tau pathology can be seeded and propagated. 
A similar pathological propagation phenomenon has been 
reported in a number of studies, for e.g., tau extracted from 
human AD brains [113, 114] and from mice exposed to trau-
matic brain injury (TBI) [115].
Both in vitro and in vivo studies of tau propagation have 
been facilitated with the use of pre-formed fibrils (PFF) of 
tau, originally developed in the laboratory of John Trojanow-
sky and Virginia Lee [116]. Experiments performed with 
tau PFFs, both in vitro and in vivo, have revealed that tau 
can propagate trans-synaptically from one neuron to another, 
and that the nearby network, synaptic contacts and neuronal 
activity modulate such propagation [117, 118], possibly 
bridging the physiological release of tau [119, 120] and the 
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pathological one [121]. Recent studies, using novel PET 
tracers binding to PHF-tau allowing real-time visualization 
of tau pathology, also support the view that progression of 
tau pathology occurs in the brains of human AD patients 
[122, 123].
It should also be taken into account that despite tau being 
a cytosolic and microtubule-associated protein, a physi-
ological role for secreted tau is possible. Some evidence 
suggests that neuronal activity can influence tau release at 
the synaptic terminal and that such release is not connected 
to propagation of tau or transfer of any type of pathology 
to neighboring neurons [119, 120]. Moreover, despite the 
origin and the degree of propagation substantially differ-
ing in different diseases, it is plausible that some common 
mechanistic features underlie the spread of pathology in 
various neurodegenerative diseases with different charac-
teristic aggregating proteins. Thus, there is a clear need for 
better understanding of the specific mechanisms that drive 
tau secretion and of the specific forms of secreted tau and 
their different pathogenicity.
Cell‑to‑cell transfer of tau
Despite the fact that tau is a microtubule-associated cytosolic 
protein, it is physiologically present outside the cells. While 
many aspects of tau secretion remain unknown, it seems that 
tau can escape from cells via multiple routes (Fig. 2). Tau 
is found in the CSF [124], and CSF of AD patients displays 
elevated levels of phosphorylated tau species that seem to 
Fig. 2  Mechanisms of cell-to-cell transfer of pathological tau pro-
tein. Pathological tau conformers can be transferred between cells 
by multiple non-exclusive mechanisms. (1) Tau secretion directly 
through the PM involves clustering of tau at the PM, interaction with 
specific lipids in cholesterol/sphingomyelin/PI(4,5)P2-rich membrane 
microdomains, penetration through the PM and release from the PM 
facilitated by cell surface HSPGs. This unconventional tau secretion 
mechanism resembles the secretion of FGF2 (UPS I-like). (2) Tau is 
secreted in ectosomes shed from the PM. Ectosomes are larger than 
exosomes and also differ in their molecular composition. After their 
release from cells, both ectosomes and exosomes function similarly 
and can be fused to or endocytosed by target cells. (3) Secretion of 
tau in exosomes and via organelle hitchhiking. Tau can be packed in 
exosomes by inward budding of late endosome membrane leading to 
formation of intraluminal vesicles in multivesicular bodies (MVB) 
that can be secreted by fusion of MVB membrane with the PM. Other 
organelle hitch-hiking (UPS III-like) pathways possibly involved 
in secretion of tau and other misfolded cytosolic proteins include 
secretory endo-lysosomes, related to the autophagy-lysosomal path-
way. The MAPS pathway promotes secretion of cytosolic misfolded 
proteins by chaperone-mediated capture of misfolded cytosolic pro-
teins to the ER, followed by secretion via fusion of endo-lysosomal 
vesicles with the PM releasing vesicle-free tau in the extracellular 
space. (4) Cell-to-cell transfer of tau seeds via tunneling nanotubes 
that directly connect the cytosols of two neighboring cell. Regard-
less of the secretion pathway, tau aggregates eventually reach the 
cytosol of the recipient cells, allowing templated seeding of healthy 
tau molecules into misfolded pathological conformations. The recipi-
ent cells can then propagate the pathology further to other previ-
ously unaffected cells. It is currently unclear which ones of the above 
mechanisms are involved in synaptic release of tau, and whether the 
synaptic release of physiological and pathological forms of tau are 
mediated by the same mechanism(s)
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correlate with increased disease severity [124, 125]. These 
findings suggest a prominent role for extracellular tau in 
disease pathogenesis and progression. Importantly, while a 
fraction of tau found in the cerebrospinal fluid may be asso-
ciated with passive release of the intracellular content from 
dying cells, multiple lines of evidence suggest that active 
cellular processes are involved in tau secretion.
Some studies have shown that tau is secreted at the synap-
tic terminus during normal synaptic activity [119, 120]. This 
constitutive and physiological secretion of tau has not been 
directly linked to propagation of pathological forms of tau to 
neighboring neurons, although the long-term effects of phys-
iologically secreted tau are not known yet. It is also possible 
that secreted monomeric tau could have some yet unknown 
physiological signaling activity. Other studies, however, 
suggest that presynaptic neuronal activity may modulate 
the release and trans-synaptic transfer of pathological tau 
[126, 127]. Furthermore, in animal models pathological 
tau appears to be more localized to synapses compared to 
non-pathological tau [63], and synaptosomes isolated from 
human AD brains were shown to contain more phospho-
rylated and aggregated tau than in healthy controls [64]. 
Although several studies have demonstrated that presynaptic 
neuronal activity enhances tau release, the mechanism of 
this phenomena, however, remains poorly understood. Neu-
ronal depolarization or the associated presynaptic activity 
and  Ca2+ response can modulate the release of two types of 
extracellular vesicles, ectosomes and exosomes [128, 129]. 
Indeed, Wang and colleagues have demonstrated that depo-
larization of neurons promotes the release of tau-containing 
exosomes [127]. Pooler et al., however, suggested that syn-
aptic activity mainly modulates non-exosomal secretion of 
tau, through a mechanism dependent on the release of syn-
aptic vesicles [119]. While it is still controversial how tau 
secretion occurs from synaptic terminals, whether associ-
ated with vesicles or via vesicle-free mechanism, it seems 
that in pathological conditions synapses are important for 
the spread of the pathogenic protein. Pathological spread 
of another misfolded protein, α-synuclein, was recently 
shown to occur via the brain connectome [130] and it is 
plausible that similar neuronal network-mediated spread of 
tau pathology happens in tauopathies. This is supported by 
the evidence showing that the transmission of tau pathology 
occurs via a trans-synaptic mechanism, and that the pattern 
of spread is determined by synaptic connectivity rather than 
spatial proximity [131].
While in vivo studies have been critical for determining 
the cross-species seeding abilities of different pathologi-
cal tau strains [132] and in demonstrating that pathologi-
cal inclusions from human brains affected with tauopathies 
induce NFT formation in rodents, often recapitulating the 
disease-specific features of the original inclusion [113, 133, 
134], the molecular mechanisms underlying tau propagation 
remain challenging to assess in vivo. In vitro approaches 
have significantly contributed to our understanding of the 
basic mechanisms involved in the cell-to-cell transfer of tau 
pathology by, e.g., showing that morphologically distinct tau 
seeds can induce similar types of tau aggregates in recipient 
cells, surprisingly faithfully recapitulating morphological 
features of tau aggregates [74, 135]. Diverse molecular path-
ways that are involved in cell-to-cell transfer of pathological 
tau have been identified, drawing a heterogeneous landscape 
of mechanisms by which tau can exit cells and enter neigh-
boring cells. Table 2 summarizes the currently available 
evidence supporting various cellular mechanisms involved 
in secretion of tau. There has been much focus on vesicular 
mechanisms, including exosomal secretion and release in 
PM-shed ectosomes, but also reports on vesicle-free secre-
tion resulting in naked vesicle-free tau in the extracellular 
space. Different mechanisms are also involved in cellular 
uptake of vesicular tau and vesicle-free tau, and this likely 
affects the efficiency of cellular uptake, subcellular localiza-
tion of internalized tau and the overall seeding potency of 
different forms of tau and in different cell types.
In addition to transfer of tau between cells via the extra-
cellular space, a direct intercellular mechanism via tunneling 
nanotubes allows transport of cytosolic tau directly from the 
cytoplasm of one cell to the cytoplasm of another cell [136] 
(Fig. 2). Tunneling nanotubes, up to 100-μm long communi-
cation paths between cells [137], have been shown to deliver 
pathological protein aggregates, including PrP, α-synuclein, 
tau, huntingtin and Aβ, in naked form or associated with lys-
osomes [138]. Interestingly, tunneling nanotubes can medi-
ate the transfer of pathological proteins not only between 
two neuronal cells, but between astrocytes as well [139]. 
Moreover, intracellular misfolded tau has been shown to 
promote the formation of tunneling nanotubes [140], pos-
sibly as an attempt to clear the cytoplasm from toxic proteins 
that cannot be otherwise cleared. However, the formation of 
tunneling nanotubes—or cellular contacts in other forms—is 
not required for cell-to-cell transfer of tau oligomers and 
aggregates, as several studies have shown that tau pathology 
can be transferred from one cell to another via the extracel-
lular medium without cell-to-cell contacts or presence of 
donor cells [118, 121].
Vesicle‑mediated mechanisms of tau secretion
Cellular protein secretion mechanisms are classified into 
conventional and unconventional. Conventional secretion 
mechanisms include the classical secretory route, also 
known as endoplasmic reticulum (ER)–Golgi pathway, for 
proteins that carry a signal peptide, which directs them to 
the ER membrane [141]. A vast majority of secreted pro-
teins use the classical secretory route. It is estimated that 
39% of the human protein-coding genes will produce one or 
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more products with a signal peptide, and 15% will produce 
a conventionally secreted protein product (proteinatlas.org). 
Unconventional secretion covers all the other routes, from 
PM pore formation [unconventional protein secretion type 
I (UPS I)] to organelle hitchhiking and exosomal secretion 
[unconventional protein secretion type III (UPS III)] and 
Golgi bypass [unconventional protein secretion type IV 
(UPS IV)] [142]. Unconventional protein secretion pathways 
are in most cases induced by cellular stress and are thus an 
important cellular survival strategy under proteostatic stress.
Different secretion mechanisms involving vesicular struc-
tures have been suggested for tau. One mechanism is UPS 
III-like and relies on intracellular structures, such as multi-
vesicular bodies or endo-lysosomes, and may result in the 
secretion of tau inside small extracellular vesicles (~ 40 to 
120 nm in diameter) called exosomes, but also in release of 
free tau, unbound to vesicles, through the fusion of endo-lys-
osomes with PM. Another mechanism, called microvesicle 
shedding, does not involve intracellular vesicular structures. 
The tau-containing vesicles are formed directly by outward 
budding of the PM, resulting in the secretion of tau in larger 
extracellular vesicles (~ 100 to 1000 nm in diameter) called 
ectosomes.
Exosomes are generated in multivesicular bodies, a type 
of late endosomes, following inward budding of the outer 
endosomal membrane. Tau has been reported to be found 
in exosomes purified from brains of tau(P301L) transgenic 
mice [143, 144] and in exosomes isolated from neuroblas-
toma cells and from cerebrospinal fluid of AD patients 
[145]. Importantly, exosomes may deliver pathological tau 
to unaffected cells, seeding further tau pathology. Neuron-
derived exosomes extracted from plasma of mild cognitive 
impairment (MCI) and AD patients are able to promote 
tau pathology in wild-type mice [146]. Finally, cell-to-cell 
transfer of tau via exosomes can be facilitated by microglia, 
whose role in prion-like propagation of protein aggregates 
remains incompletely understood [147].
Besides multivesicular bodies, tau may also be found in 
endo-lysosomes. Fusion of endo-lysosomes with the PM 
releases tau and other proteins to the extracellular space in 
a vesicle-free form [148]. Tau may be delivered to endo-
lysosomes by multiple protein trafficking pathways. First, 
during cellular stress and overloading of the ubiquitin–pro-
teasome clearing system, a misfolding-associated protein 
secretion pathway (MAPS) can be activated to translocate 
misfolded proteins, including tau, to endo-lysosomes for 
secretion to the extracellular space [148, 149]. The MAPS 
pathway involves the initial capture of misfolded proteins 
by the chaperone ubiquitin carboxyl-terminal hydrolase 19 
(USP19) at the extracellular surface of ER. Then, co-chap-
erones Hsc70 and DNAJC5 mediate the sorting of misfolded 
cargos into the lumen of endo-lysosomes [148, 150]. Alter-
natively, dysfunctional cytoplasmic proteins and protein Ta
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aggregates can be delivered to endo-lysosomes through mac-
roautophagy [148]. Several reports have suggested a role of 
macroautophagy in tau secretion [151–154]. It is not clear, 
however, if autophagosomes deliver tau to endo-lysosomes 
for secretion or if they are capable of directly fusing to the 
PM for cargo release.
Ectosomes are larger than exosomes and are generated 
by outward budding of the PM rather than originating from 
intracellular multivesicular bodies [155]. Tau has been found 
in ectosomes purified from neuroblastoma cells, primary 
cortical neurons, mouse brain interstitial fluid (ISF) [155], 
and from cerebrospinal fluid of AD patients and healthy 
controls [156]. Interestingly, tau secretion in ectosomes was 
suggested to be a normal physiological phenomenon, while 
exosomal tau secretion may prevail under pathological con-
ditions [155, 156].
It thus appears that tau utilizes different non-exclusive 
routes to overcome cellular membrane barriers and to exit 
the cell. It seems plausible that under proteostatic stress, the 
cells would activate multiple unconventional secretion path-
ways to clear the cytoplasm from the misfolded and aggre-
gated proteins which endanger cellular survival. It is not 
clear yet whether different conformational tau species have 
preferred release pathways, and whether the pathogenicity 
of different conformers depends on them.
It is important to note that many of the studies that have 
reported secretion of tau in exosomes or ectosomes also 
demonstrated that a significant fraction of extracellular tau 
appears to be in the vesicle-free form. Additionally, some 
studies have described the secretion mechanisms utilized 
by tau independent of vesicular secretion (Table 2 and dis-
cussed below). The high relative level of vesicle-free tau 
compared to tau found in extracellular vesicles could be 
explained by three scenarios: (1) tau may be secreted in a 
free, non-vesicle-associated form, with a minority secreted 
in vesicles, (2) tau may be secreted exclusively in vesicles, 
but rapidly escaping most of the vesicles, or (3) tau may be 
secreted exclusively in free form, but may associate with 
extracellular vesicles after secretion. While most likely these 
scenarios are not mutually exclusive, increasing body of evi-
dence suggests that tau release to the extracellular space may 
occur via unconventional secretion directly through the PM.
Tau secretion directly through the plasma 
membrane
Several studies suggest that while a fraction of the total 
extracellular tau is indeed found in exosomes or ecto-
somes, a large fraction of the extracellular tau pool exists 
in vesicle-free form [149, 155, 157, 158] (Table 2). Two 
recent studies demonstrated that tau secretion can occur 
via a type I mechanism of unconventional protein secre-
tion (UPS I), i.e., by direct translocation across the PM [67, 
159]. Using complementary methodological approaches, 
both groups concluded that direct secretion of tau through 
the PM involves the following key steps: (1) recruitment and 
clustering of tau at the cytosolic leaflet of the PM involv-
ing hyperphosphorylation of tau and specific lipids such as 
phosphatidyl inositol 4,5 phosphate (PI(4,5)P2) cholesterol 
and sphingolipids, and (2) release from the PM facilitated by 
binding to heparan sulfate proteoglycans (HSPG) located at 
the extracellular leaflet of the PM (Fig. 2). Although neither 
paper presented direct evidence of membrane pore forma-
tion, Katsinelos and colleagues showed that tau was capable 
of disrupting large unilamellar vesicle (LUV) membranes 
in a PI(4,5)P2-dependent manner [67]. Interestingly, many 
of these mechanistic aspects of tau secretion have signifi-
cant similarity to the unconventional secretion of fibroblast 
growth factor 2 (FGF2), one of the most widely studied 
unconventionally secreted proteins [160].
Tau localizes to the PM in a clustered manner, and this 
localization is enhanced by overexpression or hyperphos-
phorylation, possibly as a consequence of increased levels 
of cytosolic tau or enhanced aggregation. Transmission 
electron microscopy revealed two types of tau clusters, with 
diameter ranging between 50 and 200 nm, at or very close to 
the PM [159]. Similar, reversible cation-sensitive clustering 
of tau has been previously reported for recombinant human 
tau in supported brain lipid membranes [161]. Experiments 
with large unilamellar vesicles (LUVs) demonstrated that tau 
and particularly its phosphomimetic mutant or hyperphos-
phorylated forms are able to bind to PI(4,5)P2 and this inter-
action may be required for membrane binding of tau [67]. 
Several groups have shown that phosphorylation promotes 
tau secretion through the PM [66, 67], although one study 
correlates tau recruitment to the PM with hypophosphoryl-
ated states [162]. While FGF2 secretion requires specific 
phosphorylation by the Tec kinase at Y82, tau secretion 
seems to depend on the general level of phosphorylation 
rather than phosphorylation of a specific amino acid residue 
[67, 163, 164]. Plasma membrane localization and secretion 
of phosphomimetic mutant of tau were enhanced compared 
to wild-type tau [67]. Furthermore, the phospho-specific 
tau antibodies AT8 (Ser202/Thr205) and PHF13 (Ser396) 
stained mostly tau at or near the PM in neuroblastoma cells 
overexpressing tau [159]. Other post-translational modifica-
tions may also be involved in the secretion process. The two 
cysteine residues, located in the R2 and R3, may play a role 
in tau secretion as suggested by findings that at least some 
secreted tau species are disulfide bridged [165]. FGF2 secre-
tion also involves intermolecular disulfide bridge formation, 
which may serve as a driver for FGF2 oligomerization at 
the membrane [166]. While there is no known mechanistic 
or pathophysiologic link between tau and FGF2, the simi-
larities in their secretion mechanisms raises the possibility 
that tau could obtain a specific conformational state which 
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may be able to engage an FGF2-like unconventional protein 
secretion mechanism at the PM. More broadly, this high-
lights the importance of UPS in understanding how patho-
logical proteins may be released from cells.
To escape cells directly through the PM (or other mem-
branes), tau would have to be able to interact with the mem-
brane lipids. Indeed, tau interacts with both biological [13, 
162, 167–170] and artificial membranes [17, 50, 171–175]. 
Binding of tau to membranes in vitro is enhanced by the 
presence of anionic lipids such as phosphatidyl serine (PS) 
and PI(4,5)P2 [17, 67, 172, 175]. In a cellular context, tau 
may also require the presence of cholesterol and sphingo-
myelin for membrane interaction and penetration, indicating 
that cholesterol and sphingomyelin-dependent membrane 
microdomains (also called “lipid rafts”) may play a role in 
this process [18, 159, 176]. Interestingly, tau may also dis-
rupt ordered membrane domains and may thus affect the 
function of the PM more broadly [173].
Binding of tau to membranes has several important, 
related consequences that may affect its physiological and 
pathological functions and its secretion process. Firstly, tau 
can deform membranes in vitro. Tau can induce micellariza-
tion of anionic fatty acids [177] and deform micelles [17]. 
When tau was incubated with vesicles, tau–lipid complex 
formation resulted in morphological deformation of the vesi-
cles [175]. Importantly, while individual MTBDs of tau can 
induce vesicle lysis [174]), full-length tau does not seem 
to share this activity, so tau membrane interaction does not 
seem to cause cell death per se [172]. To date, however, 
no biological consequences for this membrane deformation 
have been directly shown. Second, tau clusters [159, 161] 
and fibrillizes upon binding to anionic lipid membranes [49, 
172, 177]. Tau fibrillization requires the presence of nega-
tively charged nucleator, and anionic lipids in membranes 
can serve such a function. The inner leaflet of the PM of 
animal cells is composed of about 20% of anionic lipids 
that provide negative charges and create an electrostatic field 
for the inner leaflet. Thus, anionic membranes located at 
the inner leaflet of the PM can recruit tau to the PM and 
nucleate tau fibrillization. Third, tau, a natively unstruc-
tured protein acquires α-helical conformation upon bind-
ing to membranes. The MTBDs of tau, especially R2 and 
R3, have been shown to undergo context-dependent fold-
ing on lipid membranes [17, 171, 175, 178]. The forming 
α-helices are amphipathic, and mutating key hydrophobic 
residues in the helices inhibit binding of tau to membranes 
[175] and may therefore be important in tau secretion. These 
helices do not penetrate deeply into the lipid bilayer, but 
could act as molecular tweezers to extract negatively charged 
phospholipids from the membrane [17, 175]. Similar short 
α-helices are also formed upon tau binding to microtubules 
[179], indicating that context-dependent folding of tau may 
take place with several interaction partners. Tau interaction 
with PM may also be partially mediated by interaction of 
tau N-terminus to PM-located proteins, such as annexin A2 
and annexin A6 [180]. While membrane localization, defor-
mation and membrane-dependent folding (and secretion) of 
tau could be important for the pathological forms of tau, it 
remains unclear if the lipid and membrane interactions play 
a role in physiological functions of tau in healthy cells.
A critical step in FGF2 secretion is the formation of a 
membrane pore by membrane-penetrating FGF2 oligom-
ers. Tau was shown to disrupt membranes by forming 
pore-like amyloid structures [181, 182]. Importantly, post-
translational modifications and pathological mutations 
may enhance this property [181, 182]. Tau aggregation/
oligomerization inhibitors significantly suppressed secre-
tion of human tau overexpressed in cultured cells as well as 
endogenous tau from murine primary neurons [159]. While 
direct evidence of formation of membrane pores during the 
secretion process is lacking, these findings suggest that tau 
could penetrate the PM through an oligomerization‐medi-
ated process, somewhat similarly to FGF2. Interestingly, 
other disease-associated proteins, such as α-synuclein and 
Aβ, also have the ability to form bacteriotoxin-like annu-
lar protofibrils and pore-like structures in membranes [183, 
184], suggesting that this mechanism could play a central 
role in unconventional secretion of several misfolded aggre-
gating proteins capable of transcellular propagation. Impor-
tantly, membrane disruption by protofibrils could also pro-
vide an escape route from vesicles, both during the secretion 
process and after cellular uptake.
Lastly, like FGF2, tau secretion was also shown to depend 
on HSPG on cell surface to complete the translocation 
across the PM [67, 159]. Tau has long been known to bind 
to GAGs in vitro, and heparin is widely used as a promoter 
of tau aggregation [185, 186]. Tau secretion was efficiently 
suppressed when the cellular level of glycosaminoglycans 
(GAGs) was decreased by treatment with either sodium chlo-
rate, a compound that inhibits sulfation of newly synthesized 
GAGs, or with heparinases, enzymes that specifically cleave 
heparin and heparan sulfate-type sulfated glycans [67, 159]. 
Chondroitinase ABC did not alter tau secretion indicating 
that HSPGs, but not chondroitin sulfate proteoglycans, are 
involved in the tau secretion process. Furthermore, tau secre-
tion was impaired in  CHO745 cells, which are deficient in the 
synthesis of proteoglycans due to lack of xylosyl transferase 
activity, but could be returned to almost normal level when 
wild-type cells were added to the culture, suggesting that 
even the presence of GAGs on neighboring cells is sufficient 
to facilitate tau secretion [67]. Importantly, sodium chlorate 
was able to reduce the secretion of endogenous tau from 
primary neurons [67, 159] suggesting that physiological 
secretion of tau may also involve GAGs. Altogether, these 
data suggest an important role for cell surface proteoglycans, 
specifically HSPGs, in tau secretion.
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Cellular uptake and templated misfolding of tau 
in recipient cells
After being secreted to the extracellular space, pathologi-
cal tau oligomers, monomers or aggregates need to enter 
another cell via a process called cellular uptake. Following 
cellular uptake, pathological tau seeds may be degraded, 
re-secreted or can mediate the misfolding of healthy tau mol-
ecules in the recipient cells (Fig. 2). As for secretion, diverse 
cellular mechanisms can mediate tau internalization from 
the extracellular space. Recipient cells seem to favor low 
molecular weight, short tau fibrils over tau monomers and 
larger filaments [187], which may at least partially determine 
the potency of various tau aggregate species for cellular 
propagation [188]. Importantly, uptake of tau aggregates is 
not specific for neurons, and cell-to-cell transfer is likely to 
occur also between neurons and glial cells. Close proximity 
of the PMs of the donor and recipient cells, as is the case 
in synapses, appears to facilitate cell-to-cell transfer of tau 
aggregates [118].
Tau oligomers can be internalized by dynamin-dependent 
bulk endocytosis and transported within recipient cells in the 
endo-lysosomal pathway [187]. Micropinocytosis, another 
type of bulk and non-specific endocytosis, seems to play 
a central role in pathological tau uptake both in vitro and 
in vivo [189, 190], as well as for other pathologically mis-
folded proteins such as α-synuclein, TDP-43 [191], and PrP 
[192]. Before being internalized by micropinocytosis, tau 
binds to HSPGs on the PM, which promote the rearrange-
ments of the membrane prior to endocytosis [189]. Binding 
of tau to HSPGs appears to be crucial for internalization 
to occur, and 6-O-sulfation pattern of the heparan sulfate 
sidechains was reported to be a critical determinant for tau 
binding [193]. Interestingly, heparin-like GAG mimetics can 
mask the HSPG binding site on tau, resulting in reduced cell 
surface binding, uptake and seeding of tau oligomers [189].
HSPG-dependent macropinocytosis is initiated by small 
protein aggregates, and tau trimers were shown to be the 
minimum size to initiate this mechanism [193, 194]. In line 
with this, a recent study demonstrated that different tau spe-
cies can be internalized by different cellular mechanisms 
[195]. Macropinocytosis is the preferred entry route for tau 
monomers and small oligomers (although they can also be 
internalized by endocytosis), while dynamin-dependent 
endocytosis is favoured for bigger aggregates.
Macropinocytosis and HSPGs may also be responsible for 
the uptake of whole exosomes [196], although it is possible 
that exosomes are internalized as a result of the unspecificity 
of micropinocytosis. In general, endocytosis and/or pinocy-
tosis has been reported to be a favored internalization route 
for exosomes over direct fusion to the PM [197, 198].
Specific interactions with cell surface receptors may be 
involved in internalization and toxicity of tau oligomers. For 
example, tau interacts with muscarinic receptors, which may 
mediate tau internalization via clathrin-mediated endocy-
tosis and contribute to tau toxicity by disrupting calcium 
homeostasis [199]. Blockage of muscarinic receptors indeed 
attenuates tau-mediated neurotoxicity in vitro [20].
Once tau is internalized from the extracellular space into 
the endosomes, it must find a way to escape the endosomal 
vesicles to interact with and template misfolding of cytosolic 
healthy tau molecules and to fully propagate the pathology 
to the recipient cells. Tau is indeed capable of rupturing the 
endosome membrane [200, 201], although the molecular 
mechanisms of this process, or which forms of tau mediate 
it, have not been fully elucidated. Organized tau conforma-
tions such as annular protofibrils and pore-forming struc-
tures [181, 182] could be involved in mediating tau escape 
from endo-lysosomal vesicles by disrupting the membrane 
in a manner recalling the escape of viruses or bacteria from 
endosomes [202]. Interestingly, C-terminal fragments of tau-
containing MTBDs may be particularly effective in lysing 
vesicles [172, 174].
The concept of transcellular propagation of misfolding 
pathology implies that a pathological protein aggregate 
originating from a single or a restricted group of cells is 
able to promote pathology broadly to different brain areas in 
a way that the further misfolded and aggregated molecules 
resemble in morphology and pathogenicity of the original 
seed. Accumulating evidence demonstrates the ability of 
pathological tau to be internalized and to drive the conver-
sion of healthy tau molecules into pathological aggregates, 
both in vitro and in vivo [112, 118, 133, 188]. Moreover, 
the morphological features of the original tau seeds can be 
faithfully recapitulated in the newly formed tau aggregates 
[74, 135]. Moreover, specific monomeric conformers have 
been shown to have different intrinsic abilities to become 
pathogenic, and they can give rise to a limited amount of 
strains, suggesting that the misfolding is closely related to 
the structure of the original seed [40, 41].
Although mechanistic data are slowly emerging, it still 
remains unclear how the templated misfolding and seeding 
occurs at the molecular level. Two models have been pro-
posed to explain the template seeding of endogenous tau. 
In the first model, called template-assisted growth, patho-
logical oligomers act as templates for unfolded monomers, 
which are progressively packed into β-sheet structures and 
stabilized by hydrogen bonds [203, 204]. This model could 
explain the rapid process of tau fibrillization in vitro. In the 
second model, shared with PrP and Aβ [205] and called 
oligomer-nucleated conformational induction, monomers 
are not directly assembled into bigger aggregates, but they 
oligomerize before being incorporated into fibrils [206]. 
Unfolded tau monomers are stabilized to the highest energy 
state to constitute the seed of rearranged proteins, which 
then accelerates the assembly process [206, 207].
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However, the pathway of tau fibrillization may not be as 
straightforward as it seems. A recent study demonstrated 
that different stable monomeric forms of tau with different 
seeding abilities coexist, implying that different seeds could 
originate from their aggregation [40]. This study also raises 
the possibility that tau, despite being natively unfolded, 
may physiologically exist in relatively stable conforma-
tions that affect its propensity to adopt a pathological form. 
Additionally, the complex pattern of tau post-translational 
modifications may also contribute to generation of different 
conformers. Different tau pools might have slightly differ-
ent aggregation properties leading to formation of different 
pathological aggregates of the same protein, with distinct 
structural composition, shape, toxicity and ultimately dif-
ferent disease specificity [74].
It is also important to note that, similarly to other dis-
ease-associated low complexity proteins [208–210], tau can 
undergo liquid–liquid phase separation, where tau separates 
into liquid-like droplets similarly as in a water–oil demixing 
event [58, 211]. This process is mediated by the MTBDs and 
by electrostatic interactions between the negatively charged 
N-terminus and positively charged C-terminus [58, 212]. 
Liquid–liquid phase separation spatially concentrates tau 
molecules, possibly favoring tau homo-oligomerization and 
aggregation. The concept that liquid–liquid phase separa-
tion may be transformed into permanent aggregation is now 
validated for several RNA-binding proteins associated with 
different neuropathological conditions [213]. Interestingly, 
TIA-1, an RNA-binding protein centrally involved in the for-
mation of stress granules [214], has been shown to directly 
modulate tau pathology in vitro and in vivo [215, 216]. Inter-
estingly, TIA-1-dependent recruitment of internalized tau 
oligomers to stress granules has been suggested to provide 
a hub for tau toxicity and seeding in recipient cells [190].
Further considerations for understanding 
propagation of tau pathology in brain tissue
Microglia play important and diverse roles in neurodegen-
erative diseases. Microglia have beneficial functions, such 
as clearing cellular debris, protein aggregates and dying 
cells, but can also contribute to disease pathogenesis by, 
e.g., abnormal synapse elimination and chronic pro-inflam-
matory cytokine secretion [217]. Post-mortem studies with 
patients affected by different tauopathies revealed deposits 
of aggregated tau in reactive microglia [218]. As microglia 
do not normally express tau, this indicates that microglia 
had engulfed tau aggregates from the extracellular space, 
or as a part of engulfed debris from dead neurons. It has 
been shown that microglia have the ability to internalize 
tau to degrade it [219–221]. However, when the amount of 
aggregating protein surpasses the degradation capabilities 
of microglia, toxic tau aggregates appear in the cytoplasm 
and promote microglial dysfunction [222]. While a corre-
lation between microglia activation and spreading of tau 
pathology has been reported [223], the actual role of micro-
glia in actively transferring pathological tau to neurons, 
and importantly also which forms of pathological tau are 
transferred, has been unclear. Importantly, microglia are 
able to promote cell-to-cell spreading of pathological tau 
by secreting it themselves [147]. In this study, microglia 
internalized neuronally secreted tau from the extracellular 
space and packed it in exosomes—which appear to contain 
the most toxic forms of tau [127, 155]. Consistently, when 
exosome formation was inhibited, tau propagation in neu-
rons was reduced both in vitro and in vivo. Furthermore, 
depletion of microglia strongly suppressed propagation of 
tau pathology in human tau(P301S) expressing transgenic 
mice [147]. Additionally, astrocytes are also able to inter-
nalize both fibrillar and monomeric tau, implicating a pos-
sible role for other glial cells in the process of spreading the 
pathology [224, 225].
Factors affecting tau secretion or uptake, or efficiency of 
clearance of tau seeds from the brain interstitial fluid and 
CSF, likely affect the rate of disease progression in tauopa-
thies. Genetic variants are known to contribute to the CSF 
levels of tau [226, 227]. However, currently it is not clear if 
and how genetic factors modulate individual susceptibility 
and rate of disease progression by altering propagation of 
tau pathology in the brain. Some mechanistic connections 
have been reported between late-onset AD risk gene function 
and tau secretion [157]. Moreover, expression and activities 
of several enzymes participating in generation and modifi-
cation of sulfated glycosaminoglycans, particularly heparan 
sulfate sulfotransferases, have been reported to be altered 
in AD brain and to affect accumulation of phosphorylated 
tau species [228, 229]. While altered levels and function 
of HSPGs may relate to many aspects of AD pathogenesis, 
including ApoE function and growth factor activity in the 
brain, it is notable that HSPGs appear to play a key role in 
both secretion and uptake of pathological tau species.
One important contributor to clearance of tau aggregates 
from the brain is the brain glymphatic system, a brain-wide 
interstitial solute clearance system composed of astrocytes, 
paravascular routes and dural lymphatics [230, 231]. Clearance 
of extracellular tau from the brain was significantly impaired 
in mice lacking functional central nervous system lymphatic 
system [232]. Importantly, the glymphatic system function can 
be adversely affected by stroke, traumatic brain injury or other 
comorbidities, such as type 2 diabetes, which could enhance 
spreading of tau pathology in the brain [233, 234]. Similar to 
brain levels of Aβ, sleep–wake cycle regulates brain ISF and 
CSF levels of tau in humans [235]. In P301S transgenic mice, 
increased wakefulness and sleep disruption increased ISF and 
CSF tau levels, tau aggregation and spreading over longer 
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periods of time [236], suggesting that alterations in tau clear-
ance can have a strong impact on progression of tau pathology.
There appears to be an intriguing connection between neu-
ronal activity and tau secretion. Increased neuronal activity 
stimulates tau release in cultured cortical neurons [119], in 
human tau-overexpressing transgenic mice in vivo [120] and 
in human iPSC neurons [121]. Moreover, enhanced neuronal 
activity accelerates development and spreading of tau pathol-
ogy in the brains of rTg4510 mice [121]. These data implicate 
that not only the pathological forms of tau, but also physiologi-
cal “healthy” forms of tau are secreted by neurons in a manner 
that is regulated by neuronal activity. Currently, it is unclear 
which of the mechanisms involved in secretion of pathologi-
cal forms of tau are also utilized in neuronal release of non-
pathological forms of tau. HSPGs appear to be at least partially 
involved also in secretion of endogenous non-pathological 
forms of tau in cultured rodent neurons [67, 159]. Whether the 
neuronally secreted tau species are pathological and can seed 
tau pathology in neighboring cells could simply be determined 
by their conformational state. Somewhat unexpectedly, even 
tau monomers may carry such conformational information, as 
suggested by a recent study [41].
The findings that hyperexcitability promotes tau secretion 
may have important implications in the progression of tau 
pathology in AD patients. Aβ is known to promote hyperex-
citability and subclinical epileptiform activity may contribute 
to cognitive decline in AD [237, 238]. It is possible that in 
regions vulnerable to early tauopathy, such as the hippocam-
pus, amyloid pathology could trigger or promote the release 
and propagation of pathogenic tau seeds. In rTg4510 mice, 
optogenetic stimulation of the hippocampus leads to robust 
worsening of tau pathology [121], providing some experimen-
tal support for this type of mechanism.
Finally, all studies addressing tau secretion mechanisms 
should be performed thorough characterization of the secreted 
tau species, vesicular and non-vesicular, to improve compara-
bility and interpretation of data from different sources. Another 
factor complicating comparison of different tau secretion stud-
ies is that some studies use full-length tau protein, while others 
use tau fragments, typically containing one or more MTBDs, 
yet the conclusions from most studies are generalized to tau 
(implicating the full-length tau protein). The diversity of tau 
arises from multiple levels, including splicing, conformational 
states, morphology of aggregates and filaments, and how this 
diversity is connected to transcellular propagation of tau is 
only beginning to be addressed.
Concluding remarks
The presence of tau in the cerebrospinal fluid of AD patients 
was long considered a mere consequence of passive release 
from degenerating and dying neurons. Accumulating 
evidence over the last decade has convincingly shown that 
tau and other neurodegeneration-associated intracellular 
amyloid proteins, such as α-synuclein, TDP-43 and SOD1, 
can be actively secreted from cells and that these extracel-
lular protein aggregates, or seeds, can propagate the misfold-
ing pathology to healthy cells. It now seems that cell-to-cell 
transmission is a common mechanism for disease progres-
sion in most, if not all, neurodegenerative diseases.
Disruption of proteostasis can be particularly detrimental 
to neurons. Accumulation of misfolded aggregated proteins 
in cells triggers multiple cellular mechanisms that jointly 
aim to restore proteostasis and improve cell viability. Not 
surprisingly, pathological forms of tau can be secreted via 
multiple non-exclusive mechanisms, including both vesicu-
lar and non-vesicle-mediated pathways, some of which 
appear to be induced by accumulation of protein aggregates 
in cells. Also, unconventional protein secretion directly 
through the PM, similar to FGF2 secretion (UPS I-like), 
has recently been reported for tau. Many amyloid proteins 
have long been known to be membrane active, and formation 
of membrane pores may be involved in tau secretion but also 
in the escape of tau from vesicles, both in the extracellular 
space and after internalization to recipient cells. Although 
tau is considered a natively unfolded protein it appears to 
be capable of context-dependent folding, which could be 
important for both the aggregation process but also for the 
membrane interaction and secretion processes.
Tau aggregates can be diverse in terms of their morphol-
ogy such as reflecting slightly different conformational states 
of the aggregated tau protein. It is currently unclear if par-
ticular secretion pathways are preferred by certain species of 
tau aggregates. It is noteworthy that recent studies suggest 
that even tau monomers may carry conformational informa-
tion that can be replicated during the templated misfolding 
process, which can be propagated through generations of 
cells.
The fact that tau is physiologically secreted independently 
of aggregation raises the question if some forms of extra-
cellular tau could have a yet undiscovered function in the 
nervous system. Whether physiological secretion of non-
pathological forms of tau in neurons occurs via the same 
or overlapping mechanisms as the pathological forms of 
tau needs to be clarified in future studies. Importantly, both 
physiological and pathological secretion of tau appears to 
be connected to neuronal activity. The role of glial cells and 
the glymphatic system in the clearance and propagation of 
pathological protein aggregates deserves more attention in 
the future.
It is possible that cellular secretion and uptake mecha-
nisms for the diverse range of disease-associated amyloid 
proteins are at least partially overlapping. Better understand-
ing of the mechanisms of pathological protein propagation 
is expected to help develop novel therapeutic strategies for 
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slowing down the progression of neurodegenerative dis-
eases. For instance, the development of monoclonal anti-
bodies or other compounds that specifically target, sequester 
or disassemble tau conformations involved in the propaga-
tion of pathology could slow down disease progression in 
tauopathies. Alternatively, inhibition of the processes that 
promote tau interaction with plasma membrane lipids or 
cell surface proteoglycans may decrease the extracellular 
pool of tau available for internalization by neighboring cells. 
Inhibition of the uptake of secreted tau species or interfer-
ing with the templated misfolding or stress granule asso-
ciation of tau in the recipient cells could provide another 
therapeutic strategy for halting transcellular propagation of 
tau pathology. However, mechanistically we should first aim 
at better understanding of the different roles and functions of 
physiological vs pathological forms of secreted tau and also 
clarify whether the same, overlapping and distinct secretion 
mechanisms are responsible for secretion of the two different 
pools of extracellular tau.
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